Multinational health technology company Philips may be hit with a class action after its sleep therapy machines were subject to an urgent safety recall over concerns customers could inhale degrading foam.
Swiss pharmaceutical company Biogen has filed another lawsuit accusing an Australian generic drug manufacturer of infringing the patent for its blockbuster multiple sclerosis drug Tecfidera.
A judge has slammed an “absurd” class action settlement offer made by pelvic mesh device maker Astora Women’s Health that would require Shine Lawyers to provide the company with indemnities, saying “no rational judge” would approve it.
Pharmaceutical giant Bristol-Myers Squibb will fight a case brought by Merck Sharp & Dohme alleging misuse of market power over stage IV melanoma treatments, telling the Federal Court on Friday it denied its rival’s claims.
The Australian Securities and Investments Commission has filed court action against a multi-million dollar Western Australian biotech company, alleging it made several misleading representations to the market during the height of the COVID-19 pandemic.
Generic drug maker Mayne Pharma Group has been hit with a shareholder class action over disclosures in relation to price-fixing allegations by US authorities.
Melbourne hospital operator Western Health has been hit with a class action on behalf of junior doctors across six hospitals in Victoria who allege they were denied pay for overtime hours, the third underpayments class action filed by doctors in the state.
IP Australia has refused to register a patent acquired by Elanco Australasia from Bayer covering a lice treatment, after amendments failed to address findings that the patent lacked an inventive step.
A judge has hit women’s activewear company Lorna Jane with a $5 million penalty for representing to consumers during the height of the coronavirus crisis last year that its activewear would protect them from viruses including COVID-19.
A proposal by Bristol-Myers Squibb-owned Celgene to split a second trial into two more hearings in a dispute over patents covering the pharmaceutical maker’s top selling cancer drug Revlimid would result in wasted costs, wasted time and require a second judge, a court has been told.